Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations
H Hasegawa, H Yasuda, J Hamamoto, K Masuzawa… - Lung Cancer, 2019 - Elsevier
Objectives Epidermal growth factor receptor (EGFR) mutation-positive lung cancer accounts
for a significant subgroup of non-small cell lung cancers (NSCLC). Approximately 4–10% of …
for a significant subgroup of non-small cell lung cancers (NSCLC). Approximately 4–10% of …
Treatment of patients with non-small-cell lung cancer with uncommon EGFR mutations in clinical practice
Y Yamada, T Tamura, Y Yamamoto… - Anticancer …, 2020 - ar.iiarjournals.org
Background/Aim: To describe real clinical outcomes in patients with non-small cell lung
cancer who have uncommon epidermal growth factor receptor (EGFR) mutations. Materials …
cancer who have uncommon epidermal growth factor receptor (EGFR) mutations. Materials …
[HTML][HTML] Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR …
F Barrón, AF Cardona, L Corrales… - Journal of thoracic …, 2018 - ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations has
a distinct biology and heterogeneous clinical behavior. We evaluated the characteristics to …
a distinct biology and heterogeneous clinical behavior. We evaluated the characteristics to …
[HTML][HTML] Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and …
Abstract Objectives In a phase Ib trial, afatinib plus cetuximab demonstrated promising
clinical activity (objective response rate [ORR]: 29%; median progression-free survival [PFS] …
clinical activity (objective response rate [ORR]: 29%; median progression-free survival [PFS] …
Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
CH Huang, JS Ju, TH Chiu, ACC Huang… - … Journal of Cancer, 2022 - Wiley Online Library
The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) afatinib improves
survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed …
survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed …
[HTML][HTML] Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation …
M Kimura, F Yasue, E Usami… - Molecular and …, 2018 - spandidos-publications.com
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib,
erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non …
erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non …
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
BC Liao, CC Lin, JH Lee, JCH Yang - Lung Cancer, 2017 - Elsevier
The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),
gefitinib and erlotinib, and the second-generation EGFR-TKI, afatinib, have all been …
gefitinib and erlotinib, and the second-generation EGFR-TKI, afatinib, have all been …
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
MJ Hochmair, A Morabito, D Hao, CT Yang… - Future …, 2018 - Taylor & Francis
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …
Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
J Ribeiro Gomes, MRS Cruz - OncoTargets and therapy, 2015 - Taylor & Francis
Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have
shown effectiveness for advanced non-small-cell lung cancer (NSCLC) with activating …
shown effectiveness for advanced non-small-cell lung cancer (NSCLC) with activating …
Real-life effectiveness of afatinib versus gefitinib in patients with non-small-cell lung cancer: a Czech multicentre study
M Svaton, M Bratová, O Fischer, J Krejci… - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-
small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) …
small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) …